FDA Drafts More Labels for Products That Are Both Drugs and Devices
Published Date: 6/26/2025
Notice
Summary
The FDA just dropped a draft guide to help companies understand how to label combo products with unique device IDs (UDIs). If you make or work with products that mix drugs and devices, this affects you! Comments on the draft are open until September 24, 2025, so jump in now to shape the final rules—this could save time and money by making tracking easier.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 0 costs, 1 mixed.
Draft UDI Guidance for Combination Products
The FDA released a draft guidance titled "Unique Device Identifier (UDI) Requirements for Combination Products" to help industry and FDA staff understand how UDI rules apply to products that combine drugs, devices, and/or biologics. The draft guidance explains UDI labeling and submission to the Global Unique Device Identification Database (GUDID) and invites comments by September 24, 2025.
NDC-Bearing Co-Packaged Products Could Be Treated Differently
The draft guidance notes that some co-packaged combination products that properly bear a National Drug Code (NDC) may be able to identify device constituent parts using the product identifier and the product's quality system (for example, device model number and lot/batch). FDA explicitly requests public comment on what approach or approaches it should take in these circumstances (see section III.B. of the draft guidance).
Guidance Is Non‑Binding; Alternatives Allowed
The draft guidance, when finalized, will represent FDA's current thinking but is not binding on FDA or the public. The document states you may use an alternative approach if it satisfies the requirements of applicable statutes and regulations.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Previous / Next Documents
Previous: 2025-11805, Applications for New Awards; Rehabilitation Training: Innovative Rehabilitation Training Program
The U.S. Department of Education is inviting applications for the Innovative Rehabilitation Training program to fund fresh, effective training for rehab professionals helping people with disabilities. Eligible groups like states, nonprofits, and colleges can apply starting June 30, 2025, with a deadline of July 28, 2025. This program aims to boost rehab services by teaching new skills that match today’s workforce needs, backed by federal funding.
Next: 2025-11808, Elimination of Green and Energy Efficient Mortgage Insurance Premium Rate Category Applicable to Section 232 Mortgages
Starting August 25, 2025, HUD will stop offering a special lower mortgage insurance rate for green and energy-efficient healthcare facility loans. Instead, all these loans will pay the regular rate that was set before. This change affects anyone applying for FHA-insured healthcare facility loans and means no more discounts for energy-saving features.